Skip to content

Study · Non-randomized trial · n = 17 · 1991

15 results

Bone mass in endometriosis patients treated with GnRH agonist implant or danazol.

Dodin S, Lemay A, Maheux R, Dumont M, Turcot-Lemay L

Obstetrics and gynecology1 Mar 1991Cited by 45 (Europe PMC)

PMID1825135 (opens in a new tab)PepBankPUB-01825135
Publisher pageAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In women with endometriosis, monthly goserelin suppressed estradiol into the menopausal range.

    In plain wordsIn women with endometriosis, monthly goserelin reduced estradiol into the menopausal range.

    Peptide
    Goserelin
    Outcome
    DecreaseSerum estradiol
    Study

    n = 17

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  2. 02HumanNon-randomized trialSafety outcome

    In women with endometriosis, lumbar spine bone mineral content fell by 5.7% after three months of goserelin.

    In plain wordsIn women with endometriosis, lower spine bone mineral content fell by 5.7% after three months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar spine bone mineral content at three months
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implant · 3 monthsAs given in this study (human).

    Measurements

    Lumbar spine change
    −5.7%
    3 months

    Source sentences

    Summary
    Mean decreases from pre-treatment values in the lumbar spine and femoral neck were -5.7 and -3.8% at 3 months and -8.2 and -7.7% at 6 months of treatment, respectively; lumbar spine values were significantly different (P less than .05) from those of the control group, whose values changed little during the same period.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  3. 03HumanNon-randomized trialSafety outcome

    In women with endometriosis, femoral neck bone mineral content fell by 3.8% after three months of goserelin.

    In plain wordsIn women with endometriosis, thigh bone neck mineral content fell by 3.8% after three months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseFemoral neck bone mineral content at three months
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implant · 3 monthsAs given in this study (human).

    Measurements

    Femoral neck change
    −3.8%
    3 months

    Source sentences

    Summary
    Mean decreases from pre-treatment values in the lumbar spine and femoral neck were -5.7 and -3.8% at 3 months and -8.2 and -7.7% at 6 months of treatment, respectively; lumbar spine values were significantly different (P less than .05) from those of the control group, whose values changed little during the same period.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  4. 04HumanNon-randomized trialSafety outcome

    In women with endometriosis, lumbar spine bone mineral content fell by 8.2% after six months of goserelin.

    In plain wordsIn women with endometriosis, lower spine bone mineral content fell by 8.2% after six months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar spine bone mineral content at six months
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implant · 6 monthsAs given in this study (human).

    Measurements

    Lumbar spine change
    −8.2%
    6 months

    Source sentences

    Summary
    Mean decreases from pre-treatment values in the lumbar spine and femoral neck were -5.7 and -3.8% at 3 months and -8.2 and -7.7% at 6 months of treatment, respectively; lumbar spine values were significantly different (P less than .05) from those of the control group, whose values changed little during the same period.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  5. 05HumanNon-randomized trialSafety outcome

    In women with endometriosis, femoral neck bone mineral content fell by 7.7% after six months of goserelin.

    In plain wordsIn women with endometriosis, thigh bone neck mineral content fell by 7.7% after six months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseFemoral neck bone mineral content at six months
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implant · 6 monthsAs given in this study (human).

    Measurements

    Femoral neck change
    −7.7%
    6 months

    Source sentences

    Summary
    Mean decreases from pre-treatment values in the lumbar spine and femoral neck were -5.7 and -3.8% at 3 months and -8.2 and -7.7% at 6 months of treatment, respectively; lumbar spine values were significantly different (P less than .05) from those of the control group, whose values changed little during the same period.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  6. 06HumanNon-randomized trialActivity measurement

    In women with endometriosis, urinary calcium-creatinine ratio significantly increased above baseline during goserelin treatment.

    In plain wordsIn women with endometriosis, the urine calcium-creatinine ratio increased above baseline during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseUrinary calcium-creatinine ratio during treatment
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Significant increases over baseline values were also observed in urinary calcium-creatinine ratio and serum alkaline phosphatase.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  7. 07HumanNon-randomized trialActivity measurement

    In women with endometriosis, serum alkaline phosphatase significantly increased above baseline during goserelin treatment.

    In plain wordsIn women with endometriosis, blood alkaline phosphatase increased above baseline during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    IncreaseSerum alkaline phosphatase during treatment
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Significant increases over baseline values were also observed in urinary calcium-creatinine ratio and serum alkaline phosphatase.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, normal menses returned within two months after goserelin cessation.

    In plain wordsIn women with endometriosis, normal periods returned within two months after goserelin stopped.

    Peptide
    Goserelin
    Outcome
    Not applicableReturn of normal menses
    Study

    n = 17

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Normal menses returned within 2 months after cessation of either medication.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  9. 09HumanNon-randomized trialSafety outcome

    In women six months after goserelin cessation, lumbar spine mineral content remained reduced but did not significantly differ from pretreatment values.

    In plain wordsIn women six months after goserelin stopped, lower spine mineral content remained reduced but did not significantly differ from pretreatment values.

    Peptide
    Goserelin
    Outcome
    No significant changeLumbar spine recovery versus pretreatment
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Six months after goserelin treatment, the lumbar spine and femoral neck bone mineral content was still reduced but to values not significantly different from the pre-treatment and control values; urinary calcium-creatinine ratio was decreased, whereas serum alkaline phosphatase was still elevated.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  10. 10HumanNon-randomized trialSafety outcome

    In women six months after goserelin cessation, femoral neck mineral content remained reduced but did not significantly differ from pretreatment values.

    In plain wordsIn women six months after goserelin stopped, thigh bone neck mineral content remained reduced but did not significantly differ from pretreatment values.

    Peptide
    Goserelin
    Outcome
    No significant changeFemoral neck recovery versus pretreatment
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Six months after goserelin treatment, the lumbar spine and femoral neck bone mineral content was still reduced but to values not significantly different from the pre-treatment and control values; urinary calcium-creatinine ratio was decreased, whereas serum alkaline phosphatase was still elevated.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  11. 11HumanNon-randomized trialActivity measurement

    In women six months after goserelin cessation, urinary calcium-creatinine ratio decreased.

    In plain wordsIn women six months after goserelin stopped, the urine calcium-creatinine ratio decreased.

    Peptide
    Goserelin
    Outcome
    DecreaseUrinary calcium-creatinine ratio after cessation
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Six months after goserelin treatment, the lumbar spine and femoral neck bone mineral content was still reduced but to values not significantly different from the pre-treatment and control values; urinary calcium-creatinine ratio was decreased, whereas serum alkaline phosphatase was still elevated.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  12. 12HumanNon-randomized trialActivity measurement

    In women six months after goserelin cessation, serum alkaline phosphatase remained elevated.

    In plain wordsIn women six months after goserelin stopped, blood alkaline phosphatase remained elevated.

    Peptide
    Goserelin
    Outcome
    IncreaseSerum alkaline phosphatase after cessation
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Six months after goserelin treatment, the lumbar spine and femoral neck bone mineral content was still reduced but to values not significantly different from the pre-treatment and control values; urinary calcium-creatinine ratio was decreased, whereas serum alkaline phosphatase was still elevated.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  13. 13HumanNon-randomized trialSafety outcome

    In women with endometriosis, lumbar spine bone mineral content during goserelin treatment was significantly lower than control values.

    In plain wordsIn women with endometriosis, lower spine bone mineral content during goserelin treatment was lower than control values.

    Peptide
    Goserelin
    Outcome
    DecreaseLumbar spine bone mineral content versus controls
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Mean decreases from pre-treatment values in the lumbar spine and femoral neck were -5.7 and -3.8% at 3 months and -8.2 and -7.7% at 6 months of treatment, respectively; lumbar spine values were significantly different (P less than .05) from those of the control group, whose values changed little during the same period.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  14. 14HumanNon-randomized trialSafety outcome

    In women six months after goserelin cessation, lumbar spine mineral content did not significantly differ from control values.

    In plain wordsIn women six months after goserelin stopped, lower spine mineral content did not significantly differ from control values.

    Peptide
    Goserelin
    Outcome
    No significant changeLumbar spine recovery versus controls
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Six months after goserelin treatment, the lumbar spine and femoral neck bone mineral content was still reduced but to values not significantly different from the pre-treatment and control values; urinary calcium-creatinine ratio was decreased, whereas serum alkaline phosphatase was still elevated.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.
  15. 15HumanNon-randomized trialSafety outcome

    In women six months after goserelin cessation, femoral neck mineral content did not significantly differ from control values.

    In plain wordsIn women six months after goserelin stopped, thigh bone neck mineral content did not significantly differ from control values.

    Peptide
    Goserelin
    Outcome
    No significant changeFemoral neck recovery versus controls
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Monthly implantAs given in this study (human).

    Source sentences

    Summary
    Six months after goserelin treatment, the lumbar spine and femoral neck bone mineral content was still reduced but to values not significantly different from the pre-treatment and control values; urinary calcium-creatinine ratio was decreased, whereas serum alkaline phosphatase was still elevated.
    1 context sentence
    Summary · context
    In 17 subjects treated with a monthly goserelin implant, serum estradiol (E2) levels were suppressed into the menopausal range.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.